Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03446040 · ClinicalTrials.gov registry record · Phase 1
An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
NCT03446040 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 92 participants.
The verdict
NCT03446040, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether BMS-986258 both monotherapy and in combination with Nivolumab is safe and tolerable in the treatment of advanced malignant tumors.
Interventions
- BIOLOGICAL Nivolumab
- DRUG rHuPH20
- BIOLOGICAL BMS-986258
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2018-03-08 |
| Est. Completion | 2024-08-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03446040
The ClinicalTrials.gov registry entry for NCT03446040 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT03446040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03446040 about?
NCT03446040 is a clinical study titled "An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread". The purpose of this study is to determine whether BMS-986258 both monotherapy and in combination with Nivolumab is safe and tolerable in the treatment of advanced malignant tumors.
What is the current status of trial NCT03446040?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2018-03-08. Estimated completion is 2024-08-29.
What interventions are being tested in trial NCT03446040?
The interventions under investigation include: Nivolumab (BIOLOGICAL), rHuPH20 (DRUG), BMS-986258 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03446040?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.